Pennsylvania Attorney General Dave Sunday filed a lawsuit alleging several major pharmaceutical companies and pharmacy benefit managers conspired to artificially inflate insulin prices by more than 1,000%, driving up out-of-pocket costs for residents.
The Office of Attorney General’s Antitrust Section filed the complaint in the Commonwealth Court of Pennsylvania. The filing alleges violations of Pennsylvania’s Unfair Trade Practices and Consumer Protection Law, as well as civil conspiracy and unjust enrichment. State officials claim the defendants engaged in deceptive market practices to generate abnormally high medication prices.
The lawsuit names pharmaceutical manufacturers Eli Lilly and Company, Novo Nordisk Inc. and Sanofi-Aventis US LLC as defendants. The complaint also targets major pharmacy benefit managers, including Express Scripts, CVS Caremark and Optum RX.
Attorney General Dave Sunday emphasized the impact of the alleged price manipulation on state residents.
“Millions of Pennsylvanians have diabetes or prediabetes and they were all potentially harmed by this scheme to artificially inflate pricing to maximize company profits,” Sunday said. “Our Antitrust Section will continue to hold accountable companies, large and small, that prioritize profits over public access to affordable life-saving medication and care.”
Sunday says approximately 1.3 million Pennsylvanians live with diabetes and another 3.5 million residents have prediabetes. Diagnosed diabetes costs Pennsylvania an estimated $16.4 billion each year.
The lawsuit seeks injunctive relief that would mandate structural changes among the companies. These changes aim to lower costs to fair market prices and expand patient options. It also seeks restitution for harmed Pennsylvanians, along with civil penalties and court costs.
Download the FREE WPXI News app for breaking news alerts.
Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
©2026 Cox Media Group





